Drug survival of apremilast in patients treated for psoriasis in a real-world setting - 19/09/18
Doi : 10.1016/j.jaad.2018.03.028
Erica B. Lee, BS a, Mina Amin, MD b, Jashin J. Wu, MD c, ⁎ 
a John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii
b University of California, Riverside, School of Medicine, Riverside, California
c Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California
∗Reprint requests: Jashin J. Wu, MD, Kaiser Permanente Los Angeles Medical Center, Department of Dermatology, 1515 North Vermont Ave, 5th Floor, Los Angeles, CA 90027Kaiser Permanente Los Angeles Medical CenterDepartment of Dermatology1515 North Vermont Ave, 5th FloorLos AngelesCA90027
| Dr Amin is currently with the Department of Medicine, Kaiser Permanente Los Angeles Medical Center. |
|
| Funding sources: None. |
|
| Conflicts of interest: Dr Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and Regeneron. The rest of the authors have no conflicts of interest to disclose. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 79 - N° 4
P. 760-761 - octobre 2018 Retour au numéro
Article précédent
- Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: A retrospective study evaluating long-term efficacy and safety
- Abdallah Khemis, Awatef Kelati, Henri Montaudié, Jean-Philippe Lacour, Thierry Passeron
- Malignant melanoma associated with chronic once-daily aspirin exposure in males: A large, single-center, urban, US patient population cohort study from the “Research on Adverse Drug events And Report” (RADAR) project
- Kelsey A. Orrell, Ahuva D. Cices, Nicholas Guido, Sara Majewski, Erin Ibler, Thy Huynh, Stephanie M. Rangel, Anne E. Laumann, Mary C. Martini, Alfred W. Rademaker, Dennis P. West, Beatrice Nardone
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?